Actualités Abliva Ab - 0QDU | Actions London Stock Exchange

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/...

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/...

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND...

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND...

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/...

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/...

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire STOCKHOLM, Nov. 20, 2019 - Continued Progress in KL1333...

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM...

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire STOCKHOLM, Aug. 21, 2019 Focus on genetic mitochondrial diseases...

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019...

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 PR Newswire LUND, Sweden, Aug. 20, 2019 LUND, Sweden, Aug...

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire LUND, Sweden, July 27, 2019 LUND, Sweden, July 27, 2019...

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire LUND, Sweden, July 27, 2019 LUND, Sweden, July 27, 2019...

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire LUND, Sweden, 4 July 2019 LUND, Sweden, 4 July 2019...

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire LUND, Sweden, 4 July 2019 LUND, Sweden, 4 July 2019...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Abliva Ab (0QDU)

Votre Hub pour des idées et discussions en direct en temps réel

0QDU Actualités

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Abliva Ab (0QDU) Actualités

Abliva Ab (0QDU)

Votre Hub pour des idées et discussions en direct en temps réel

0QDU Actualités

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités